

Michele Spina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/754475/publications.pdf>

Version: 2024-02-01

315
papers

11,599
citations

26567

56
h-index

37111

96
g-index

323
all docs

323
docs citations

323
times ranked

10793
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism. <i>Clinical Nutrition</i> , 2022, 41, 698-708.	2.3	21
2	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	2.5	12
3	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	0.8	8
4	Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi. <i>Tumori</i> , 2021, 107, 91-94.	0.6	11
5	A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the CARMEN phase II trial. <i>British Journal of Haematology</i> , 2021, 192, 119-128.	1.2	7
6	Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. <i>European Journal of Haematology</i> , 2021, 106, 697-707.	1.1	1
7	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	0.8	74
8	Immunodeficiency-associated Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 547-559.	1.0	7
9	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. <i>Annals of Hematology</i> , 2021, 100, 2547-2556.	0.8	1
10	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e72-e75.	1.7	11
11	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	2.0	43
12	Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study. <i>Annals of Hematology</i> , 2020, 99, 283-291.	0.8	5
13	Nonpegylated liposomal doxorubicin combination regimen (COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020, 38, 478-486.	0.8	15
14	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , 2020, 7, e284-e294.	2.2	78
15	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. <i>Hematological Oncology</i> , 2020, 38, 257-265.	0.8	7
16	The Management of HIV-Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 335-347.	0.2	0
17	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , 2019, 134, 798-801.	0.6	53
18	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019, 60, 2890-2898.	0.6	8

#	ARTICLE	IF	CITATIONS
19	The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 378-384.	0.6	3
20	Graphene Oxide increases mammalian spermatozoa fertilizing ability by extracting cholesterol from their membranes and promoting capacitation. <i>Scientific Reports</i> , 2019, 9, 8155.	1.6	13
21	LONG-TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT). <i>Hematological Oncology</i> , 2019, 37, 256-257.	0.8	0
22	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. <i>Blood</i> , 2019, 134, 398-398.	0.6	10
23	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	0.6	64
24	Native Bovine and Porcine Pericardium Respond to Load With Additive Recruitment of Collagen Fibers. <i>Artificial Organs</i> , 2018, 42, 540-548.	1.0	11
25	Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	1.2	49
26	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	1.7	90
27	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018, 36, 68-75.	0.8	34
28	Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. <i>Bone Marrow Transplantation</i> , 2018, 53, 228-230.	1.3	7
29	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , 2018, 8, 108.	2.8	32
30	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	2.8	22
31	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2018, 103, 1345-1350.	1.7	45
32	Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi. <i>Blood</i> , 2018, 132, 393-393.	0.6	26
33	Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study. <i>Blood</i> , 2018, 132, 5294-5294.	0.6	4
34	Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7548-7548.	0.8	1
35	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	0.8	12
36	Hodgkin Lymphoma in Patients with HIV Infection. , 2018, , 1008-1015.		0

#	ARTICLE	IF	CITATIONS
37	The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. <i>Blood</i> , 2018, 132, 2890-2890.	0.6	0
38	Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years. <i>Blood</i> , 2018, 132, 1688-1688.	0.6	0
39	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2017, 102, e203-e206.	1.7	21
40	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e137-e146.	2.2	28
41	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017, 4, e15-e23.	2.2	106
42	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i> , 2017, 390, 555-566.	6.3	444
43	ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC) "Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. <i>European Journal of Cancer</i> , 2017, 81, 45-55.	1.3	33
44	Cardiac Disease and Lifestyle Risk Factors Following Hodgkin Lymphoma: An EORTC Lymphoma Group and GELA Follow-Up Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S139-S140.	0.4	1
45	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446.	1.7	11
46	REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 234 RELAPSED/REFRACTORY CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2017, 35, 170-171.	0.8	0
47	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017, 102, 1931-1935.	1.7	11
48	Improving Provision of Care for Long-term Survivors of Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e1-e9.	0.2	17
49	Low-dose radiotherapy in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 472-479.	0.8	9
50	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1615-1621.	1.8	27
51	Natural Scaffolds for Regenerative Medicine: Direct Determination of Detergents Entrapped in Decellularized Heart Valves. <i>BioMed Research International</i> , 2017, 2017, 1-9.	0.9	12
52	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017, 8, 91703-91710.	0.8	21
53	The Vietnamese pig as a translational animal model to evaluate tissue engineered heart valves: promising early experience. <i>International Journal of Artificial Organs</i> , 2017, 40, 142-149.	0.7	13
54	CD205, a target antigen for a novel antibody drug conjugate (ADC): Evaluation of antigen expression on non-Hodgkin lymphoma (NHL). <i>Journal of Clinical Oncology</i> , 2017, 35, e14039-e14039.	0.8	1

#	ARTICLE	IF	CITATIONS
55	A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL). <i>Annals of Oncology</i> , 2016, 27, vi316.	0.6	1
56	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85
57	Central nervous system involvement in <sc>AIDS</sc>-related lymphomas. <i>British Journal of Haematology</i> , 2016, 173, 857-866.	1.2	19
58	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a <sc>SIE</sc>, <sc>SIES</sc>, and <sc>GITMO</sc> consensus paper. <i>European Journal of Haematology</i> , 2016, 97, 554-561.	1.1	9
59	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 2677-2680.	0.6	2
60	Decellularized aortic conduits: could their cryopreservation affect post-implantation outcomes? A morpho-functional study on porcine homografts. <i>Heart and Vessels</i> , 2016, 31, 1862-1873.	0.5	24
61	PO-0666: Comparing the efficacy of low-dose radiotherapy in patients with aggressive and indolent lymphomas. <i>Radiotherapy and Oncology</i> , 2016, 119, S311.	0.3	0
62	PO-0665: Compliance with ILROG guidelines in the treatment of extranodal lymphomas; an internal plans review. <i>Radiotherapy and Oncology</i> , 2016, 119, S310.	0.3	0
63	New treatment strategies for HIV-positive cancer patients undergoing antineoplastic chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2391-2403.	0.9	7
64	Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. <i>Infectious Agents and Cancer</i> , 2016, 11, 27.	1.2	38
65	PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis Research</i> , 2016, 140, S177.	0.8	16
66	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2375-2381.	0.6	7
67	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1823-1830.	0.6	30
68	Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program. <i>Blood</i> , 2016, 128, 2985-2985.	0.6	4
69	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. <i>Blood</i> , 2016, 128, 3033-3033.	0.6	2
70	Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2016, 128, 472-472.	0.6	2
71	Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7538-7538.	0.8	2
72	HIV-Associated Hodgkin Lymphoma. , 2016, , 119-132.		1

#	ARTICLE	IF	CITATIONS
73	Diagnosis, Prophylaxis and Treatment of Central Nervous System Involvement by Non-Hodgkin Lymphoma in HIV-Infected Patients. , 2016, , 215-221.		0
74	Cancer survivorship: Is there a role for cancer survivor clinics?. Journal of Clinical Oncology, 2016, 34, e272-e272.	0.8	0
75	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma. Blood, 2016, 128, 4161-4161.	0.6	0
76	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma. Blood, 2016, 128, 3007-3007.	0.6	0
77	The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 3049-3049.	0.6	2
78	The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. Blood, 2016, 128, 921-921.	0.6	1
79	Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial. Blood, 2016, 128, 474-474.	0.6	1
80	Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. Blood, 2015, 126, 1394-1397.	0.6	50
81	Autograft HIV-DNA Load Predicts HIV-1 Peripheral Reservoir After Stem Cell Transplantation for AIDS-Related Lymphoma Patients. AIDS Research and Human Retroviruses, 2015, 31, 150-159.	0.5	6
82	Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Annals of Oncology, 2015, 26, 958-966.	0.6	81
83	FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 2015, 26, 2155-2161.	0.6	63
84	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Haematologica, 2015, 100, 517-524.	1.7	6
85	Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications. Expert Review of Hematology, 2015, 8, 217-223.	1.0	19
86	Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leukemia and Lymphoma, 2015, 56, 921-926.	0.6	139
87	PET-adapted salvage therapy in Hodgkin's lymphoma. Lancet Oncology, The, 2015, 16, 239-240.	5.1	3
88	The prognostic value of positron emission tomography performed after two courses (<sc>INTERIM</sc>) of standard therapy on treatment outcome in early stage <sc>H</sc>odgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). American Journal of Hematology, 2015, 90, 499-503.	2.0	49
89	Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study. Blood, 2015, 126, 1541-1541.	0.6	3
90	Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2015, 33, TPS8600-TPS8600.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 3934-3934.	0.6	1
92	Lenalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) in Patients with Chemosensitive Relapse of Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT) or Experienced Relapse after Transplantation: Results of a Multicentre Phase II Trial. <i>Blood</i> , 2015, 126, 1547-1547.	0.6	1
93	Biocompatibility Issues of Next Generation Decellularized Bioprosthetic Devices. <i>Conference Papers in Science</i> , 2014, 2014, 1-6.	0.3	4
94	A new prognostic score for AIDS-related lymphomas in the rituximab-era. <i>Haematologica</i> , 2014, 99, 1731-1737.	1.7	42
95	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.	0.6	67
96	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014, 55, 38-43.	0.6	72
97	MATILDE chemotherapy regimen for primary CNS lymphoma. <i>Neurology</i> , 2014, 82, 1370-1373.	1.5	38
98	Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. <i>Human Reproduction</i> , 2014, 29, 525-533.	0.4	30
99	Is It Better to Transfer Long-Term Cancer Survivors to General Practitioners or Develop Clinics for Long-Term Survivors Within the Cancer Centers?. <i>Journal of Clinical Oncology</i> , 2014, 32, 257-257.	0.8	9
100	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	0.6	133
101	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 730-737.	5.1	164
102	Tissue-Specific Expression and Regulatory Networks of Pig MicroRNAome. <i>PLoS ONE</i> , 2014, 9, e89755.	1.1	22
103	Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Haematologica</i> , 2014, 99, 1228-1235.	1.7	69
104	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014, 99, 489-496.	1.7	55
105	Early Consolidation with High Dose Therapy and Autologous Stem Cell Transplantation in HIV-Associated Non Hodgkin Lymphoma at High Risk (aa-IPI 2-3). Mature Results of a Multicenter Prospective Phase II Trial. <i>Blood</i> , 2014, 124, 2528-2528.	0.6	2
106	Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2014, 124, 3074-3074.	0.6	1
107	Hodgkin Lymphoma in Patients with HIV Infection. , 2014, , 235-243.		0
108	HIV-Associated Lymphomas. , 2014, , 225-240.		0

#	ARTICLE	IF	CITATIONS
109	A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.. Journal of Clinical Oncology, 2014, 32, 9641-9641.	0.8	0
110	Multicenter Study with Mbvd Regimen in Elderly or Younger Patients with Cardiac Disorders Affected By Hodgkin's Lymphoma. a Phase II Study on Behalf of the Fondazione Italiana Linfomi (FIL). Blood, 2014, 124, 1732-1732.	0.6	0
111	Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL. Blood, 2014, 124, 4429-4429.	0.6	0
112	Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study. Blood, 2014, 124, 5979-5979.	0.6	0
113	Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma. Hematological Oncology, 2013, 31, 22-28.	0.8	14
114	First quantification of alpha-Gal epitope in current glutaraldehyde-fixed heart valve bioprostheses. Xenotransplantation, 2013, 20, 252-261.	1.6	113
115	Cancer-related fatigue in the elderly. Supportive Care in Cancer, 2013, 21, 2899-2911.	1.0	40
116	Nodular lymphocyte predominant Hodgkin lymphoma with non-invasive or early invasive growth pattern suggests an early step of the disease with a highly favorable outcome. American Journal of Hematology, 2013, 88, 161-162.	2.0	27
117	Tissue-Engineered Heart Valves: Intra-operative Protocol. Journal of Cardiovascular Translational Research, 2013, 6, 660-661.	1.1	8
118	Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma. Aids, 2013, 27, 1033-1035.	1.0	13
119	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica, 2013, 98, 1232-1236.	1.7	65
120	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Annals of Oncology, 2013, 24, 2108-2112.	0.6	124
121	AIDS-Related Lymphoma. , 2013, , 257-266.		0
122	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. Leukemia and Lymphoma, 2013, 54, 53-57.	0.6	42
123	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood, 2013, 122, 3251-3262.	0.6	156
124	Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anti-Cancer Drugs, 2013, 24, 212-218.	0.7	32
125	Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica, 2013, 98, 1762-1768.	1.7	27
126	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). Blood, 2013, 122, 3049-3049.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 850-850.	0.6	3
128	Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1412-1418.	0.9	1
129	Hodgkin Lymphoma in Patients with HIV Infection. , 2013, , 1-8.		0
130	Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 3055-3055.	0.6	0
131	Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 5088-5088.	0.6	0
132	NF10 Project: An International, Prospective, Observational Study Of Patients With Indolent Non-Follicular Lymphoma. Analysis Of First 215 Patients. <i>Blood</i> , 2013, 122, 1782-1782.	0.6	0
133	IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain "Restricted B-Cell Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 4080-4091.	3.2	14
134	Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2012, 17, 838-846.	1.9	114
135	Is Long-Term Fatigue in Patients With Cancer an Infrequent Symptom?. <i>Journal of Clinical Oncology</i> , 2012, 30, 4175-4175.	0.8	1
136	Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 71-76.	0.6	10
137	Two types of fatigue in cancer patients. <i>British Journal of Cancer</i> , 2012, 106, 424-424.	2.9	9
138	Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 291-299.	0.8	99
139	Fine Structure of Glycosaminoglycans from Fresh and Decellularized Porcine Cardiac Valves and Pericardium. <i>Biochemistry Research International</i> , 2012, 2012, 1-10.	1.5	51
140	Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3854-3863.	0.8	32
141	Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. <i>Blood</i> , 2012, 120, 3222-3228.	0.6	85
142	Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. <i>British Journal of Haematology</i> , 2012, 159, 252-255.	1.2	15
143	Alpha-Gal detectors in xenotransplantation research: a word of caution. <i>Xenotransplantation</i> , 2012, 19, 215-220.	1.6	59
144	Cardiomyocytes <i>In Vitro</i> Adhesion Is Actively Influenced by Biomimetic Synthetic Peptides for Cardiac Tissue Engineering. <i>Tissue Engineering - Part A</i> , 2012, 18, 725-736.	1.6	14

#	ARTICLE	IF	CITATIONS
145	Physiological Performance of a Detergent Decellularized Heart Valve Implanted for 15 Months in Vietnamese Pigs: Surgical Procedure, Follow-up, and Explant Inspection. <i>Artificial Organs</i> , 2012, 36, E138-50.	1.0	44
146	The role of diet in gastric cancer: still an open question. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 1640.	3.0	19
147	A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes. <i>Blood</i> , 2012, 120, 3682-3682.	0.6	1
148	Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012, 120, 903-903.	0.6	4
149	Massive myocardial infiltration by HIV-related non-Hodgkin lymphoma. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 836-838.	0.6	7
150	ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era. <i>Blood</i> , 2012, 120, 1564-1564.	0.6	0
151	R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study From Italian Lymphoma Foundation (FIL). <i>Blood</i> , 2012, 120, 1615-1615.	0.6	0
152	Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet ®, ¢) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (NCT01009970). <i>Blood</i> , 2012, 120, 3644-3644.	0.6	0
153	Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebo-controlled trial. <i>Diabetes and Metabolism</i> , 2011, 37, 124-130.	1.4	25
154	KIR/HLA Combination Associated with the Risk of Complications in Celiac Disease. <i>International Journal of Biological Markers</i> , 2011, 26, 221-228.	0.7	10
155	Mutations of <i>CD79A</i> , <i>CD79B</i> and <i>EZH2</i> genes in immunodeficiency-related non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2011, 152, 777-780.	1.2	16
156	Classical Hodgkin's lymphoma arising in different host's conditions: Pathobiology parameters, therapeutic options, and outcome. <i>American Journal of Hematology</i> , 2011, 86, 170-179.	2.0	29
157	Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoA reductase. <i>Journal of Lipid Research</i> , 2011, 52, 897-907.	2.0	70
158	Cells, scaffolds and bioreactors for tissue-engineered heart valves: a journey from basic concepts to contemporary developmental innovations. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 523-531.	0.6	44
159	Hodgkin's Disease in Patients with HIV Infection. <i>Advances in Hematology</i> , 2011, 2011, 1-7.	0.6	41
160	The Management of HIV-Hodgkin Lymphoma. , 2011, , 249-258.		0
161	The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi. <i>Blood</i> , 2011, 118, 2651-2651.	0.6	0
162	Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. <i>Blood</i> , 2011, 118, 2636-2636.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection. <i>Current HIV Research</i> , 2010, 8, 218-222.	0.2	19
164	The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era. <i>Cancer Epidemiology</i> , 2010, 34, 257-261.	0.8	19
165	Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 1495-1501.	2.0	30
166	Genome wide DNA-profiling of HIV-related B-cell lymphomas. <i>British Journal of Haematology</i> , 2010, 148, 245-255.	1.2	70
167	HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. <i>Tissue Antigens</i> , 2010, 75, 127-135.	1.0	22
168	Immune Recovery after Autologous Stem Cell Transplantation Is Not Different for HIV-infected versus HIV-uninfected Patients with Relapsed or Refractory Lymphoma. <i>Clinical Infectious Diseases</i> , 2010, 50, 1672-1679.	2.9	45
169	Hodgkin Lymphoma in HIV Positive Patients. <i>Current HIV Research</i> , 2010, 8, 141-146.	0.2	16
170	Therapeutic options for HIV-associated lymphomas. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2471-2481.	0.9	6
171	Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.. <i>Blood</i> , 2010, 116, 2821-2821.	0.6	2
172	Hodgkin's Disease and HIV Infection (HD-HIV): Prognostic Factors In 596 Patients (pts) within the European Group for the Study of HIV and Tumours (GECAT). <i>Blood</i> , 2010, 116, 3883-3883.	0.6	4
173	Mortality for non-AIDS-defining cancers among people with AIDS.. <i>Journal of Clinical Oncology</i> , 2010, 28, 1590-1590.	0.8	0
174	Peripheral Blood Stem Cell Mobilization In Hiv Positive Patients with Lymphoma Candidates to Autologous Transplantation: Predictive Factors Analysis for Failure or Suboptimal Stem Cell Collection. <i>Blood</i> , 2010, 116, 2250-2250.	0.6	1
175	Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL). <i>Blood</i> , 2010, 116, 1761-1761.	0.6	7
176	The changing hydrodynamic performance of the decellularized intact porcine aortic root: considerations on in-vitro testing. <i>Journal of Heart Valve Disease</i> , 2010, 19, 485-91.	0.5	12
177	Pomegranate fruit components modulate human thrombin. <i>Fá-toterapĀ-Āç</i> , 2009, 80, 301-305.	1.1	25
178	Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. <i>Journal of Medical Virology</i> , 2009, 81, 888-896.	2.5	31
179	The influence of heart valve leaflet matrix characteristics on the interaction between human mesenchymal stem cells and decellularized scaffolds. <i>Biomaterials</i> , 2009, 30, 4104-4116.	5.7	79
180	P16 Comprehensive geriatric assessment-adapted chemotherapy in elderly patients (>70 years) with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL): final results and long term follow-up. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, S24-S25.	2.0	0

#	ARTICLE	IF	CITATIONS
181	Pegylated interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2009, 145, 255-257.	1.2	60
182	Cancer in the elderly: The caregivers' perception of senior patients' informational needs. <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, e121-e125.	1.4	12
183	Influence of Dietary Feeding of Low Monomer Content Grape Seed Extract on Vitellogenin Production and Cholesterol Levels in Goldfish, <i>Carassius auratus</i> . <i>Journal of Agricultural and Food Chemistry</i> , 2009, 57, 1860-1866.	2.4	4
184	Human immunodeficiency virus-associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature. <i>Human Pathology</i> , 2009, 40, 1045-1049.	1.1	5
185	Management of Immunocompetent Patients With Primary Central Nervous System Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 353-364.	1.4	18
186	High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. <i>Blood</i> , 2009, 114, 1306-1313.	0.6	130
187	HIV-associated Hodgkin lymphoma. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 3-10.	1.5	77
188	HIV-associated lymphomas and gamma-herpesviruses. <i>Blood</i> , 2009, 113, 1213-1224.	0.6	317
189	Complete response (CR) to ifosfamide, gemcitabine, and vinorelbine (ICEV) and outcome in relapsed/refractory Hodgkin's lymphoma (HL) patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 8568-8568.	0.8	0
190	The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2008, 122, 1624-1629.	2.3	31
191	Can the caregiver replace his/her elderly cancer patient in the physician-patient line of communication?. <i>Supportive Care in Cancer</i> , 2008, 16, 1157-1162.	1.0	10
192	Mechanism of inhibition of <i>wt</i> dihydrofolate reductase from <i>E. coli</i> by tea epigallocatechin gallate. <i>Proteins: Structure, Function and Bioinformatics</i> , 2008, 72, 240-251.	1.5	38
193	Comparative evaluation of flavonoid content in assessing quality of wild and cultivated vegetables for human consumption. <i>Journal of the Science of Food and Agriculture</i> , 2008, 88, 294-304.	1.7	44
194	Recent prognostic factors in diffuse large B-cell lymphoma indicate NF- κ B pathway as a target for new therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2008, 49, 2048-2058.	0.6	29
195	Biosensor-Based Screening Method for the Detection of Aflatoxins B ₁ and G ₁ . <i>Analytical Chemistry</i> , 2008, 80, 9250-9256.	3.2	41
196	OC3.05.4 RELATIONSHIP BETWEEN GALECTIN-10 EXPRESSION AND SEVERITY OF CELIAC DISEASE ABOLISHED IN THE PRESENCE OF T CELL CLONAL EXPANSION. <i>Digestive and Liver Disease</i> , 2008, 40, S49-S50.	0.4	0
197	PA.40 IDENTIFICATION OF A NEW HLA-A*680102 VARIANT, ASSOCIATED WITH ANCESTRAL HAPLOTYPE B8-DR3 FROM TWO ITALIAN PATIENTS FROM FRIULI WITH CELIAC DISEASE. <i>Digestive and Liver Disease</i> , 2008, 40, S90.	0.4	0
198	Wheat sprout extract induces changes on 20S proteasomes functionality. <i>Biochimie</i> , 2008, 90, 790-801.	1.3	32

#	ARTICLE	IF	CITATIONS
199	FOLFOX-4 Regimen with Concomitant Highly Active Antiretroviral Therapy in Metastatic Colorectal Cancer HIV-Infected Patients: A Report of Five Cases and Review of the Literature. <i>Cancer Investigation</i> , 2008, 26, 610-614.	0.6	7
200	Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. <i>Blood</i> , 2008, 111, 5142-5151.	0.6	142
201	Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. <i>Haematologica</i> , 2008, 93, 1178-1185.	1.7	26
202	The impact of HCV co-infection on the outcome and the clinical features of HIV-related non-Hodgkin lymphoma (NHL). <i>Journal of Clinical Oncology</i> , 2008, 26, 19504-19504.	0.8	0
203	Maintenance immunotherapy after autologous bone marrow transplantation (ABMT) in relapsed follicular (R-FL) and mantle cell (R-MC) lymphomas (NHL). A monoinstitutional experience. <i>Journal of Clinical Oncology</i> , 2008, 26, 18012-18012.	0.8	0
204	Use of targeted agents in elderly cancer patients (ECP) according to the Comprehensive Geriatric Assessment (CGA). <i>Journal of Clinical Oncology</i> , 2008, 26, 20619-20619.	0.8	0
205	FOLFOX4 and concomitant highly active antiretroviral therapy (HAART) in metastatic colorectal cancer (M-CRC) HIV-positive patients (pts): A GICAT experience. <i>Journal of Clinical Oncology</i> , 2008, 26, 15046-15046.	0.8	0
206	Extranodal lymphomas in patients with HIV infection. , 2008, , 289-298.		0
207	Temozolomide as salvage treatment in primary brain lymphomas. <i>British Journal of Cancer</i> , 2007, 96, 864-867.	2.9	135
208	Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, e7-e7.	0.8	13
209	Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 35-41.	1.7	216
210	Cetuximab/Targeted Chemotherapy in an HIV-Positive Patient with Metastatic Colorectal Cancer in the HAART Era: a Case Report. <i>Journal of Chemotherapy</i> , 2007, 19, 343-346.	0.7	7
211	Dietary Folate, Alcohol Consumption, and Risk of Non-Hodgkin Lymphoma. <i>Nutrition and Cancer</i> , 2007, 57, 146-150.	0.9	23
212	High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2444-2446.	0.6	0
213	Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. <i>Digestive and Liver Disease</i> , 2007, 39, S65-S71.	0.4	20
214	Etiologic treatment of hepatitis C virus-associated mixed cryoglobulinemia. <i>Digestive and Liver Disease</i> , 2007, 39, S102-S106.	0.4	5
215	IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. <i>Bone Marrow Transplantation</i> , 2007, 40, 1019-1025.	1.3	20
216	Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. <i>British Journal of Haematology</i> , 2007, 136, 301-304.	1.2	76

#	ARTICLE	IF	CITATIONS
217	Modern management of non-Hodgkin lymphoma in HIV-infected patients. <i>British Journal of Haematology</i> , 2007, 136, 685-698.	1.2	57
218	Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells. <i>Clinical and Experimental Immunology</i> , 2007, 148, 402-409.	1.1	14
219	Effect of hydroxypropyl β -cyclodextrin on the self-assembling and thermogelation properties of Poloxamer 407. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 32, 115-122.	1.9	55
220	Role of the HLA Class II: HCV-Related Disorders. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 308-318.	1.8	19
221	Protein Expression Profile of Celiac Disease Patient with Aberrant T Cell by Two-dimensional Difference Gel Electrophoresis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 429-440.	1.8	3
222	MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients. <i>International Journal of Biological Markers</i> , 2007, 22, 307-311.	0.7	12
223	R-Dhaox, high dose chemotherapy (HDC) and rituximab maintenance as salvage treatment in relapsed/refractory (R/R) follicular (F) and mantle cells (MC) lymphomas (NHL). <i>Journal of Clinical Oncology</i> , 2007, 25, 8036-8036.	0.8	1
224	Use of biological drugs in elderly cancer patients: A sustainable reality? A mono-institutional experience. <i>Journal of Clinical Oncology</i> , 2007, 25, 19665-19665.	0.8	0
225	Ca-15.3 antigen as predictor of response to EGFR inhibitors in patients with bronchiolo-alveolar carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 18151-18151.	0.8	0
226	Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. <i>European Journal of Cancer</i> , 2006, 42, 50-54.	1.3	465
227	AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. <i>Blood</i> , 2006, 107, 3832-3840.	0.6	133
228	A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin. <i>Modern Pathology</i> , 2006, 19, 299-306.	2.9	44
229	Food groups and risk of non-Hodgkin lymphoma: A multicenter, case-control study in Italy. <i>International Journal of Cancer</i> , 2006, 118, 2871-2876.	2.3	49
230	Family History of Hemolymphopoietic and Other Cancers and Risk of Non-Hodgkin's Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 245-250.	1.1	8
231	Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients. <i>Annals of Oncology</i> , 2006, 17, 1176-1177.	0.6	8
232	Prognostic Factors in Human Herpesvirus 8-Related Lymphoproliferative Disorders Associated With HIV Infection. <i>Journal of Clinical Oncology</i> , 2006, 24, 209-209.	0.8	10
233	Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. <i>Annals of Oncology</i> , 2006, 17, 713-718.	0.6	59
234	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2006, 17, 533.	0.6	3

#	ARTICLE	IF	CITATIONS
235	MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. <i>Neurology</i> , 2006, 66, 1435-1438.	1.5	83
236	Comprehensive Geriatric Assessment-Adapted Chemotherapy in 100 Elderly Patients (>70 Years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL). <i>Blood</i> , 2006, 108, 2440-2440.	0.6	1
237	Stanford V regimen in 59 patients (pts) with HD and HIV Infection (HD-HIV): A very effective approach in the long-term analysis. <i>Journal of Clinical Oncology</i> , 2006, 24, 7583-7583.	0.8	0
238	Reactivity of an Anti NS3-HCV-Induced Autoantibody in HCV-Positive Gastric Tissue by 2D Gel Immunoblot. <i>Blood</i> , 2006, 108, 4658-4658.	0.6	0
239	Proteomic Profile of Human Gut Biopsies from Celiac Patients with and without Severe Complications. <i>Blood</i> , 2006, 108, 3899-3899.	0.6	0
240	Cancer Prevention and Early Diagnosis in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 628-629.	0.9	2
241	Rituximab for HIV-associated lymphoma: weighing the benefits and risks. <i>Current Opinion in Oncology</i> , 2005, 17, 462-465.	1.1	19
242	Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. <i>Blood</i> , 2005, 105, 1891-1897.	0.6	195
243	Smoking and non-Hodgkin lymphoma: Case-control study in Italy. <i>International Journal of Cancer</i> , 2005, 115, 606-610.	2.3	26
244	Is high-dose chemotherapy with peripheral stem cell rescue a suitable option for elderly patients affected by aggressive non-Hodgkin's lymphoma?. <i>Annals of Oncology</i> , 2005, 16, 837-838.	0.6	2
245	Characterization of Immunologic and Virological Parameters in HIV-Infected Patients with Primary Effusion Lymphoma during Antineoplastic Therapy and Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 40, 1022-1027.	2.9	34
246	Patients With HIV With Burkitt's Lymphoma Have a Worse Outcome Than Those With Diffuse Large-Cell Lymphoma Also in the Highly Active Antiretroviral Therapy Era. <i>Journal of Clinical Oncology</i> , 2005, 23, 8132-8133.	0.8	29
247	Regression of Low-Grade Non-Hodgkin's Lymphoma After Treatment With Pegylated Interferon Plus Ribavirin in Hepatitis C Virus Infection. <i>Journal of Clinical Oncology</i> , 2005, 23, 4470-4471.	0.8	8
248	Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses. <i>International Journal of Oncology</i> , 2005, 26, 945.	1.4	3
249	Peroxynitrite-mediated oxidation of the C85S/C152E mutant of dihydrofolate reductase from <i>Escherichia coli</i> : functional and structural effects. <i>Archives of Biochemistry and Biophysics</i> , 2005, 434, 221-231.	1.4	5
250	Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 4528-4528.	0.8	4
251	Final results of a multicentre phase II trial of high-dose methotrexate (HD-MTX), cytarabine, thiotepa, and idarubicin (MATILDE regimen) followed by whole-brain irradiation (WBRT) for primary CNS lymphomas (PCNSL). <i>Journal of Clinical Oncology</i> , 2005, 23, 1530-1530.	0.8	4
252	Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. <i>Cancer Research</i> , 2005, 65, 587-95.	0.4	33

#	ARTICLE	IF	CITATIONS
253	Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?. <i>Annals of Oncology</i> , 2004, 15, 1298.	0.6	1
254	Outcome in Patients with Non-Hodgkin Lymphoma and With or Without Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2004, 38, 142-144.	2.9	56
255	Hepatitis C virus infection does not prevent autologous bone marrow transplantation in HIV-related non-Hodgkin's lymphoma. <i>Aids</i> , 2004, 18, 1859-1861.	1.0	2
256	HIV-related non-Hodgkin's lymphoma (HIV-NHL) in the era of highly active antiretroviral therapy (HAART): some still unanswered questions for clinical management. <i>Annals of Oncology</i> , 2004, 15, 993-995.	0.6	14
257	Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. <i>British Journal of Cancer</i> , 2004, 90, 353-358.	2.9	130
258	Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer – a phase II trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2004, 7, 45-49.	2.0	6
259	Non-Hodgkin's lymphoma and hepatitis C virus: A case-control study from northern and southern Italy. <i>International Journal of Cancer</i> , 2004, 110, 380-385.	2.3	107
260	An IELSG International Survey of Primary Effusion Lymphoma (PEL).. <i>Blood</i> , 2004, 104, 3265-3265.	0.6	2
261	Non-Hodgkin's lymphoma (NHL) in elderly patients (pts): Patient-tailored treatment according to a comprehensive geriatric evaluation. <i>Journal of Clinical Oncology</i> , 2004, 22, 6678-6678.	0.8	0
262	High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. <i>Haematologica</i> , 2004, 89, 1100-8.	1.7	71
263	High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 6506-6506.	0.8	0
264	Therapeutic approaches to AIDS-related malignancies. <i>Oncogene</i> , 2003, 22, 6646-6659.	2.6	56
265	Hodgkin's disease in HIV. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 843-858.	0.9	29
266	Cell characterization of porcine aortic valve and decellularized leaflets repopulated with aortic valve interstitial cells: the VESALIO project (vitalitate exornatum succedaneum aorticum labore) Tj ETQq0 0 0 rgBT 0 Overlock 10 Tf 50 21	0.7	10
267	Virological efficacy in HIV-infected patients affected by non-hodgkin lymphoma, treated with antineoplastic chemotherapy and highly active antiretroviral therapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 49-53.	1.5	2
268	Improvement of Systemic Human Immunodeficiency Virus-Related Non-Hodgkin Lymphoma Outcome in the Era of Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2003, 37, 1556-1564.	2.9	76
269	Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. <i>Journal of Clinical Oncology</i> , 2003, 21, 266-272.	0.8	688
270	Comprehensive Geriatric Evaluation in Elderly Patients With Lymphoma: Feasibility of a Patient-Tailored Treatment Plan. <i>Journal of Clinical Oncology</i> , 2003, 21, 754-754.	0.8	27

#	ARTICLE	IF	CITATIONS
271	Clinical Features and Outcome of Primary Effusion Lymphoma in HIV-Infected Patients: A Single-Institution Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 3948-3954.	0.8	251
272	Impact of Concomitant Antiblastic Chemotherapy and Highly Active Antiretroviral Therapy on Human Immunodeficiency Virus (HIV) Viremia and Genotyping in HIV-Infected Patients with Non-Hodgkin Lymphoma. <i>Clinical Infectious Diseases</i> , 2003, 37, 820-827.	2.9	21
273	High-Dose Therapy and Autologous Peripheral-Blood Stem-Cell Transplantation As Salvage Treatment for HIV-Associated Lymphoma in Patients Receiving Highly Active Antiretroviral Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 4423-4427.	0.8	144
274	High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen. <i>Annals of Oncology</i> , 2003, 14, 655-656.	0.6	8
275	Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. <i>Aids</i> , 2003, 17, 137-138.	1.0	25
276	Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. <i>Annals of Oncology</i> , 2002, 13, 1341-1346.	0.6	24
277	Relevance of intraocular involvement in the management of primary central nervous system lymphomas. <i>Annals of Oncology</i> , 2002, 13, 531-538.	0.6	120
278	Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. <i>Blood</i> , 2002, 100, 1984-1988.	0.6	156
279	AIDS-related tumors: integrating antiviral and anticancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 299-315.	2.0	32
280	Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals. <i>European Journal of Cancer</i> , 2001, 37, 1306-1315.	1.3	56
281	Lymphoma in the immunosuppressed. , 2001, , 252-265.		0
282	Randomized Phase III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. <i>Journal of Clinical Oncology</i> , 2001, 19, 2638-2646.	0.8	574
283	Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients. <i>Oncology</i> , 2001, 60, 134-140.	0.9	82
284	Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 157-162.	2.0	4
285	Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. <i>Cancer</i> , 2001, 91, 155-163.	2.0	181
286	Human immunodeficiency virus-related non-Hodgkin lymphoma. <i>Cancer</i> , 2001, 92, 200-206.	2.0	27
287	Hodgkin's Disease: Clinical Presentation and Treatment. <i>Cancer Treatment and Research</i> , 2001, 104, 247-265.	0.2	7
288	Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1675-1688.	1.0	96

#	ARTICLE	IF	CITATIONS
289	Lung carcinoma in 36 patients with human immunodeficiency virus infection. , 2000, 88, 563-569.		119
290	Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection. Aids, 2000, 14, 1457-1458.	1.0	8
291	Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection. Annals of Oncology, 1999, 10, S87-S90.	0.6	16
292	Neoplastic complications of HIV infection. Annals of Oncology, 1999, 10, 1271-1286.	0.6	31
293	Hodgkin's disease in HIV-infected individuals. Current Opinion in Oncology, 1999, 11, 522.	1.1	14
294	Burkitt's lymphoma in adults with and without human immunodeficiency virus infection. Cancer, 1998, 82, 766-774.	2.0	87
295	HIV-1 infection and prostitutes. Lancet, The, 1998, 351, 1214.	6.3	0
296	Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma. Annals of Oncology, 1998, 9, 923.	0.6	24
297	Human Immunodeficiency Virus Seroprevalence and Condom Use Among Female Sex Workers in Italy. Sexually Transmitted Diseases, 1998, 25, 451-454.	0.8	34
298	HCV and HIV-Related Non-Hodgkin's Lymphoma. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 80.	0.3	3
299	Prostitution: to decriminalise or to legalise. Lancet, The, 1996, 348, 962.	6.3	0
300	Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: a single-institute study of 96 patients.. Journal of Clinical Oncology, 1996, 14, 2217-2223.	0.8	69
301	Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. , 1996, 77, 2127-2131.		39
302	LONG-TERM SURVIVAL OF PATIENTS WITH HIV-RELATED SYSTEMIC NON-HODGKIN'S LYMPHOMAS. , 1996, 14, 7-15.		14
303	Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer, 1995, 76, 535-536.	2.0	15
304	gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. International Journal of Cancer, 1995, 63, 621-626.	2.3	61
305	In vitro Proteolysis of the Red Cell Membrane in Patients with HIV Infection. Pathobiology, 1995, 63, 42-47.	1.9	0
306	Clinical Evaluation of 451 Patients with HIV Related Non-Hodgkin's Lymphoma: Experience of the Italian Cooperative Group on AIDS and Tumors (GICAT). Leukemia and Lymphoma, 1995, 20, 91-96.	0.6	19

#	ARTICLE	IF	CITATIONS
307	Clinical significance of positive direct antiglobulin test in patients with HIV infection. <i>Infection</i> , 1994, 22, 92-95.	2.3	25
308	Other cancers in HIV-infected patients. <i>Current Opinion in Oncology</i> , 1994, 6, 508-512.	1.1	8
309	Lung cancer in 19 patients with HIV infection. <i>Annals of Oncology</i> , 1993, 4, 85-86.	0.6	21
310	Hodgkin's disease in 92 patients with HIV infection: The Italian experience. <i>Annals of Oncology</i> , 1992, 3, S69-S72.	0.6	53
311	Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1992, 3, 843-847.	0.6	37
312	Condom use and high-risk sexual practices of female prostitutes in Italy. <i>Aids</i> , 1992, 6, 601.	1.0	5
313	Human immunodeficiency virus as a risk factor in miscellaneous cancers. <i>Current Opinion in Oncology</i> , 1992, 4, 907-910.	1.1	10
314	Skin carcinoma in 2 patients with HIV infection. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1184.	0.9	4
315	Lymphoma in the immunosuppressed. , 0, , 273-285.		0